Skip to content

Study · Observational study · 2026

5 results

Is Semaglutide a Safer Weight-Management Option Than Bariatric Surgery for Patients Undergoing Total Hip Arthroplasty (THA)?

Alpert Z, Katzman JL, Lajam CM, Schwarzkopf R, Rozell JC

The Journal of arthroplasty2 Sept 2025Cited by 1 (Europe PMC)

PMID40907673 (opens in a new tab)DOI10.1016/j.arth.2025.08.068 (opens in a new tab)PepBankPUB-40907673
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyOther

    In patients undergoing total hip arthroplasty, preoperative HbA1c was lowest in the semaglutide cohort (5.7%) compared with the bariatric (6.2%) and control (5.8%) cohorts.

    In plain wordsBefore hip replacement, patients using semaglutide had the lowest HbA1c compared with bariatric surgery and control patients.

    Peptide
    Semaglutide
    Outcome
    DecreasePreoperative HbA1c
    Study

    n: not reported in source

    Comparator
    Bariatric surgery and control (BMI > 35) cohorts
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Preoperative HbA1c
    5.7%
    semaglutide
    Preoperative HbA1c
    6.2%
    bariatric surgery
    Preoperative HbA1c
    5.8%
    control

    Source sentences

    Summary
    Preoperative hemoglobin A1c was lowest in semaglutide patients (6.2 versus 5.7 versus 5.8%, P < 0.001).
    1 context sentence
    Summary · context
    The study identified 224 patients who had a history of bariatric surgery, 202 patients who had perioperative semaglutide use, and a control group of 2,991 patients who had a body mass index (BMI) > 35.
  2. 02HumanObservational studyEfficacy outcome

    In patients undergoing total hip arthroplasty, the semaglutide group decreased BMI by 0.8, while control patients increased by 0.4.

    In plain wordsIn patients having hip replacement, BMI fell in those using semaglutide and rose slightly in control patients.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI change one year before and after THA
    Study

    n: not reported in source

    Comparator
    Control (BMI > 35) cohort
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    BMI decrease
    0.8 BMI points
    semaglutide
    BMI increase
    0.4 BMI points
    control

    Source sentences

    Summary
    The bariatric and semaglutide groups decreased their BMI by 1.4 and 0.8, respectively, and control patients increased by 0.4.
    2 context sentences
    Summary · context
    The changes in BMI varied across groups one year before and after THA (P < 0.001).
    Summary · context
    The study identified 224 patients who had a history of bariatric surgery, 202 patients who had perioperative semaglutide use, and a control group of 2,991 patients who had a body mass index (BMI) > 35.
  3. 03HumanObservational studySafety outcome

    In patients undergoing total hip arthroplasty, no correlation was found between the semaglutide cohort and 90-day emergency department visits.

    In plain wordsIn patients having hip replacement, semaglutide use was not linked to more emergency department visits within 90 days.

    Peptide
    Semaglutide
    Outcome
    No significant change90-day emergency department visits
    Study

    n: not reported in source

    Comparator
    Bariatric surgery and control cohorts
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no correlation found between any cohort and 90-day emergency department visits, readmissions, and all-time revision.
    1 context sentence
    Summary · context
    The study identified 224 patients who had a history of bariatric surgery, 202 patients who had perioperative semaglutide use, and a control group of 2,991 patients who had a body mass index (BMI) > 35.
  4. 04HumanObservational studySafety outcome

    In patients undergoing total hip arthroplasty, no correlation was found between the semaglutide cohort and 90-day readmissions.

    In plain wordsIn patients having hip replacement, semaglutide use was not linked to more readmissions within 90 days.

    Peptide
    Semaglutide
    Outcome
    No significant change90-day readmissions
    Study

    n: not reported in source

    Comparator
    Bariatric surgery and control cohorts
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no correlation found between any cohort and 90-day emergency department visits, readmissions, and all-time revision.
    1 context sentence
    Summary · context
    The study identified 224 patients who had a history of bariatric surgery, 202 patients who had perioperative semaglutide use, and a control group of 2,991 patients who had a body mass index (BMI) > 35.
  5. 05HumanObservational studySafety outcome

    In patients undergoing total hip arthroplasty, no correlation was found between the semaglutide cohort and all-time revision.

    In plain wordsIn patients having hip replacement, semaglutide use was not linked to more repeat (revision) surgery.

    Peptide
    Semaglutide
    Outcome
    No significant changeAll-time revision
    Study

    n: not reported in source

    Comparator
    Bariatric surgery and control cohorts
    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no correlation found between any cohort and 90-day emergency department visits, readmissions, and all-time revision.
    1 context sentence
    Summary · context
    The study identified 224 patients who had a history of bariatric surgery, 202 patients who had perioperative semaglutide use, and a control group of 2,991 patients who had a body mass index (BMI) > 35.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.